Iran vows “decisive response” to any US “miscalculation”
Iran’s joint military command warned any US interference in the Strait of Hormuz will be met with a “decisive and swift response” as tensions continue to roil negotiations, Aljazeera reported on Thursday.
Meanwhile, the US envoy to the United Nations Security Council (UNSC), Mike Waltz, warned Iran over threats to close the Strait of Hormuz during an emergency session of the UNSC.
US President Donald Trump said on Thursday that “I think they have accepted nearly everything we require.” His remarks came as Qatar reported “positive progress” after the US and Iran conclude indirect technical talks in Doha on issues related to the Memorandum of Understanding (MoU) signed on June 17.
However, Reuters reported that the US and Iran concluded a round of indirect talks on Wednesday with no sign that they had made headway toward lasting peace.
Market reaction
At press time, the WTI Oil price trades 0.60% higher at around $68.45.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The "Outlier" Investment Art in the New Era of Berky
Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India
Chevron is focusing on Argentina and the Mediterranean region, seeking global growth in liquefied natural gas, and plans to reach an agreement with India.
Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge
The upward pressure on energy prices caused by the unresolved Middle East war is mounting. New risks are also approaching, which may keep inflation above the Bank of England’s 2% target for most of next year.
AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales
Bloomberg Intelligence analyst John Murphy stated that the setback in AstraZeneca's breast cancer drug trial could reduce sales in 2035 by $2.6 billion to $3.8 billion.
Crypto prices
More
